ALDH1A1 and Patent ductus arteriosus: Markers for cancer stem cells (CSCs), including c-Met, CD133, CD44, CxCR4, ALDH1, and Sox2, have been identified in PDA and are thought to be responsible for the aggressive growth, early metastasis, high resistance to therapy, and frequent relapse despite surgery and chemotherapy [3-6].